NYSE · IDXX
Healthcare · Medical - Diagnostics & Research
$518.00
Up+$4.86 (+0.95%)
Updated Oct 10, 2026, 6:31 PM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · IDXX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
IDXX closed at $518.00 after 21 trading sessions, up 2.64% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $513.67 | $522.02 | $513.10 | $518.00 | 466.78K |
| Oct 8, 2026 | $506.67 | $514.51 | $506.12 | $513.14 | 696.68K |
| Oct 7, 2026 | $513.31 | $515.17 | $501.17 | $506.67 | 716.45K |
| Oct 6, 2026 | $529.14 | $531.38 | $512.54 | $515.41 | 502.36K |
| Oct 5, 2026 | $516.57 | $528.69 | $513.48 | $527.07 | 588.92K |
| Oct 2, 2026 | $523.50 | $524.02 | $516.02 | $518.39 | 288.82K |
| Oct 1, 2026 | $521.58 | $525.96 | $517.06 | $517.75 | 320.31K |
| Sep 30, 2026 | $531.09 | $531.11 | $521.78 | $522.19 | 503.53K |
| Sep 29, 2026 | $530.095 | $536.84 | $522.11 | $533.44 | 648.95K |
| Sep 28, 2026 | $516.53 | $530.15 | $515.12 | $529.06 | 391.99K |
| Sep 25, 2026 | $510.94 | $520.16 | $507.01 | $519.26 | 331.12K |
| Sep 24, 2026 | $520.88 | $524.12 | $511.725 | $513.39 | 328.29K |
| Sep 23, 2026 | $517.20 | $523.22 | $516.88 | $522.02 | 364.19K |
| Sep 22, 2026 | $519.27 | $523.945 | $511.73 | $521.50 | 476.54K |
| Sep 21, 2026 | $511.65 | $518.96 | $506.22 | $515.30 | 513.21K |
| Sep 18, 2026 | $506.48 | $516.43 | $505.21 | $511.65 | 1.12M |
| Sep 17, 2026 | $514.33 | $514.37 | $501.98 | $506.48 | 459.82K |
| Sep 16, 2026 | $511.56 | $520.41 | $509.02 | $513.62 | 376.07K |
| Sep 15, 2026 | $509.56 | $516.02 | $502.40 | $510.73 | 603.67K |
| Sep 14, 2026 | $510.83 | $515.48 | $505.015 | $509.56 | 454.14K |
| Sep 11, 2026 | $509.88 | $511.15 | $500.61 | $504.70 | 401.63K |
The latest Smart Investors Daily articles mentioning IDXX.
Company
Market Activity
Research & News
IDXX research
Company profile and research snapshot.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Barclays | Overweight | — |
| Aug 5, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Citigroup | Neutral | — |
| Jul 27, 2026 | UBS | Neutral | — |
| Apr 28, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
WESTBROOK, Maine, October 01, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Yahoo · Sep 30, 2026
Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX). Financial terms were not disclosed.
Yahoo · Sep 24, 2026
The companion animal diagnostics market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering an 8.7% CAGR. Growth is driven by rising pet healthcare spending, preventive care, chronic and infectious diseases, and advances in AI, molecular diagnostics, point-of-care testing and automated analyzers. Molecular diagnostics will record the fastest growth, while consumables remain the leading product segment. Asia Pacific is expected to be the fastest-growing reg
Yahoo · Sep 23, 2026
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDXX.
